#35 Veterinary pharmacovigilance part 2 ...

Human and veterinary pharmacovigilance (PV) share many goals, challenges and approaches. But there are also significant differences, such as the numerous animal species that veterinary PV needs to take into account. In this two-part episode of Drug Safety Matters, James Mount, Veterinary Pharmacovigilance assessor at the Swedish Medical Products Agency, and EU elected chair of the Pharmacovigilance Working Party for veterinary medicinal products, joins the show to talk about veterinary PV practice and its differences and similarities to human PV. 

Tune in to find out

• How the types of ADRs reported for animals and humans differ
• How the many species and breeds included in veterinary PV affect the ADR coding 
• What the Veterinary Big Data Strategy is

... and much more!

Want to know more?

• The public portal of the European Union Veterinary Pharmacovigilance Database.
• One Health – an integrated approach to the well-being of people, animals and the environment.
• A survey of veterinary professionals in Sweden, about practices and attitudes in relation to ADR reporting.
• A review of adverse events in animals and children after secondary exposure to transdermal hormone-containing medicines. 
• The EMA Big Data strategy for veterinary medicines and Data quality framework for medicines regulation
• Small Animal Veterinary Surveillance Network (SAVSNET) - University of Liverpool
• VetCompass - Royal Veterinary College, RVC
• Veterinary good pharmacovigilance practices (VGVP) | European Medicines Agency (EMA)
• Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) | European Medicines Agency (EMA)

Join the conversation on social media
Follow us on Facebook, LinkedIn, X, or Bluesky and share your thoughts about the show with the hashtag #DrugSafetyMatters.

Got a story to share?
We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!

About UMC
Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.